Skip to content

Low-dose ketamine improved brain network integrity among patients with treatment-resistant depression and suicidal ideation.

Tung-Ping Su, Li-Kai Cheng, Pei-Chi Tu, Li-Fen Chen, Wei-Chen Lin, Cheng-Ta Li, Ya-Mei Bai, Shih-Jen Tsai, Mu-Hong Chen

Psychiatry research March 1, 2025 DOI: 10.1016/j.psychres.2025.116377 via PubMed

Summary

AI-generated from the abstract

A single low-dose infusion of ketamine (0.5 mg/kg) reduced depressive and suicidal symptoms more than a low-dose midazolam infusion in 43 patients with treatment-resistant depression and suicidal ideation. Brain scans showed that ketamine increased network integrity, specifically degree centrality and clustering coefficient in the angular gyrus and degree centrality in the right thalamus. These changes in the thalamus and default-mode network may underlie ketamine's antidepressant effect.

Study at a glance

Characteristics Randomized controlled trial Peer reviewed
Sample size 43
Population Patients with treatment-resistant depression and suicidal ideation
Interventions Ketamine Midazolam
Dose 0.5 mg/kg ketamine, 0.045 mg/kg midazolam
Duration Single infusion, follow-up on day 3
Topics Depression Ketamine
Keywords Functional connectivity Graph theory Suicidal ideation Ketamine therapy
Citations 6
Key finding Low-dose ketamine infusion reduced depressive and suicidal symptoms and improved brain network integrity in the angular gyrus and right thalamus compared to midazolam.

Abstract

Ketamine is a dissociative drug used for the treatment of depression. However, the neurofunctional mechanism underlying the antidepressant effect of ketamine remains unknown. According to previous research, low-dose ketamine affects large-scale brain networks, including default-mode and salient networks. A total of 43 patients with treatment-resistant depression (TRD) and suicidal ideation (SI) were randomly assigned to receive a single infusion of either 0.5 mg/kg ketamine or 0.045 mg/kg midazolam. Depressive and suicidal symptoms were evaluated using the 17-item Hamilton Depression Rating Scale and the Columbia-Suicide Severity Rating Scale: Ideation Severity Subscale. Resting-state functional magnetic resonance imaging was performed at baseline and on day 3 after infusion. Graph theoretic metrics such as degree centrality and clustering coefficient were examined. Relative to midazolam use, low-dose ketamine infusion reduced depressive (p = 0.001) and suicidal (p = 0.025) symptoms and improved the brain network integrity, including increased degree centrality and clustering coefficient in the angular gyrus and increased degree centrality in the right thalamus. Neurofunctional changes in the thalamus and default-mode network (angular gyrus) may be associated with the antidepressant effect of ketamine on patients with TRD and SI. UMIN Clinical Trials Registry (UMIN-CTR): Registration number: UMIN000033916.

Explore topics

Comments

No comments yet.

Log in to comment